The Buffett Lens

When I think about Simon Property Group, it's a bit like owning a handful of those prime fishing holes along a well-traveled river that have drawn anglers for generations. People keep showing up not because of fancy new lures, but because the spots are in the right places where the fish naturally gather, and the leases are set up so the rights to those spots don't expire anytime soon.

This outfit has a wide moat, much like a castle protected from invaders by its prime locations and long-term leases with solid tenants. Their earnings power looks steady, with revenue climbing from near nothing in early quarters to around 1.8 billion lately and net income reaching 4.7 billion over the last twelve months. That latest return on equity hitting 96.6 percent, and even averaging over 50 percent across five years, lines up with what I've long watched for in a business: a high rate of return on the capital employed without relying on accounting tricks. The managers seem to be doing their part here, building on the strength of the properties rather than trying to row against a leaky boat. Institutional investors holding most of the shares adds a layer of oversight that suggests they're paying attention to keeping things on track.

Yet I have to say, with humility, that the debt-to-equity ratio near 6 times gives me pause. I've noted before that even a fine business can deliver poor real returns for owners if leverage gets too heavy, especially when inflation or rising rates squeeze the picture. Retail properties face real headwinds these days from folks shopping from their couches, and while the moat from location helps, it isn't armor against every economic shift. Management's own skin in the game is modest at under 2 percent, which isn't the ideal alignment I'd prefer in a long hold.

Looking ahead, the enduring value here comes from those hard-to-replicate spots and the cash they can generate over decades if the team stays focused on adapting the mix of shops, dining, and entertainment. At a price-to-earnings around 14 times and enterprise value to EBITDA near 11.5, the market isn't paying a premium that ignores the realities of slower growth ahead. Intrinsic value matters more than book figures, and if bought with an eye on holding through ups and downs, this could reward patience rather than quick trades. My own style has always been to wait for the right price on a business I understand, and this one fits that mold without promising fireworks.

For those looking to act on this, the ticker for Simon Property Group, Inc. on eToro is $SPG.

When I size up a company like Vertex Pharmaceuticals, it reminds me of a farmer who spent years experimenting with different seeds and soils, only to finally strike on a hardy strain of corn that thrives where others wither. They've built a business around medicines for serious conditions like cystic fibrosis, sickle cell disease, and a few others, turning what used to be a money-losing lab exercise into something that generates real cash for owners.

This outfit has a wide moat, much like a castle protected from invaders by thick walls and a deep moat. Their patent protections and deep research know-how keep competitors from easily copying their key treatments, such as the ones for cystic fibrosis that now reach a broad group of patients. That shows up in the numbers: latest return on equity at 22.4 percent, well above their five-year average of 16.5 percent, all while carrying almost no debt at just 0.1 times equity. I like seeing strong earnings on capital employed without leaning on borrowed money or accounting shortcuts, just as I wrote years ago about what really counts in judging a business. Revenue has climbed steadily, reaching 12.2 billion over the last four quarters with 4.3 billion in net income, and the managers running things appear to be the ones building extra value through their operating decisions rather than just riding industry tides.

Still, no business is without its humbler sides, and I always try to look at them straight on. Biotech remains a field where even talented crews can face storms if a new treatment doesn't pan out or if rivals find a better path. Their insider ownership sits low at 0.2 percent, which might suggest the folks closest to the wheel aren't as personally tied in as I'd sometimes prefer, even though big institutions own nearly all the rest and seem to like what they see. Past growth rates, as strong as they've been, can't be counted on to repeat forever, and market swings will always affect how the results look on paper. The economic boat here is better than most in the sector, but it still demands steady rowing from the management team.

At a current price around 437 dollars a share and a market value of 111 billion, the valuation lands at about 25 times earnings and 5.6 times book value. That isn't the dirt-cheap deal I hunt for in every case, but for a business with this kind of durable advantage and room to expand into new areas like acute pain or blood disorders, it could still make sense over many years if you buy with a sensible margin and hold patiently. I've seen plenty of quality companies compound nicely when owners focus on intrinsic worth rather than short-term bounces, and Vertex looks positioned to keep delivering if their research edge holds up. The key is remembering that good results come from owning the right business for the long haul, not chasing every quarterly move.

If you're considering adding this to your portfolio, the ticker for Vertex Pharmaceuticals Incorporated on eToro is $VRTX.